Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
296 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Osteoporosis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Pipeline Review, H2 2016, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape. Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 4, 8, 14, 1, 54 and 10 respectively for Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 8 and 13 molecules, respectively for Osteoporosis. Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 6 Osteoporosis Overview 7 Therapeutics Development 8 Osteoporosis - Therapeutics under Development by Companies 10 Osteoporosis - Therapeutics under Investigation by Universities/Institutes 15 Osteoporosis - Pipeline Products Glance 16 Osteoporosis - Products under Development by Companies 19 Osteoporosis - Products under Investigation by Universities/Institutes 25 Osteoporosis - Companies Involved in Therapeutics Development 26 Osteoporosis - Therapeutics Assessment 90 Drug Profiles 102 Osteoporosis - Dormant Projects 253 Osteoporosis - Discontinued Products 265 Osteoporosis - Product Development Milestones 267 Appendix 282
List of Tables
Number of Products under Development for Osteoporosis, H2 2016 21 Number of Products under Development for Osteoporosis - Comparative Analysis, H2 2016 22 Number of Products under Development by Companies, H2 2016 23 Number of Products under Development by Companies, H2 2016 (Contd..1) 24 Number of Products under Development by Companies, H2 2016 (Contd..2) 25 Number of Products under Development by Companies, H2 2016 (Contd..3) 26 Number of Products under Development by Companies, H2 2016 (Contd..4) 27 Number of Products under Investigation by Universities/Institutes, H2 2016 28 Comparative Analysis by Late Stage Development, H2 2016 29 Comparative Analysis by Clinical Stage Development, H2 2016 30 Comparative Analysis by Early Stage Development, H2 2016 31 Products under Development by Companies, H2 2016 32 Products under Development by Companies, H2 2016 (Contd..1) 33 Products under Development by Companies, H2 2016 (Contd..2) 34 Products under Development by Companies, H2 2016 (Contd..3) 35 Products under Development by Companies, H2 2016 (Contd..4) 36 Products under Development by Companies, H2 2016 (Contd..5) 37 Products under Investigation by Universities/Institutes, H2 2016 38 Osteoporosis - Pipeline by Addex Therapeutics Ltd, H2 2016 39 Osteoporosis - Pipeline by Alethia Biotherapeutics Inc., H2 2016 40 Osteoporosis - Pipeline by Alize Pharma SAS, H2 2016 41 Osteoporosis - Pipeline by Alkem Laboratories Ltd., H2 2016 42 Osteoporosis - Pipeline by AlphaMab Co., Ltd, H2 2016 43 Osteoporosis - Pipeline by Alvogen Korea Co., Ltd., H2 2016 44 Osteoporosis - Pipeline by Amgen Inc., H2 2016 45 Osteoporosis - Pipeline by Amura Holdings Limited, H2 2016 46 Osteoporosis - Pipeline by Arcarios BV, H2 2016 47 Osteoporosis - Pipeline by BiologicsMD, Inc., H2 2016 48 Osteoporosis - Pipeline by Bone Biologics, Corp., H2 2016 49 Osteoporosis - Pipeline by Bone Therapeutics SA, H2 2016 50 Osteoporosis - Pipeline by Cellmid Limited, H2 2016 51 Osteoporosis - Pipeline by Chronos Therapeutics Limited, H2 2016 52 Osteoporosis - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016 53 Osteoporosis - Pipeline by Corium International, Inc., H2 2016 54 Osteoporosis - Pipeline by Critical Pharmaceuticals Limited, H2 2016 55 Osteoporosis - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 56 Osteoporosis - Pipeline by ElexoPharm GmbH, H2 2016 57 Osteoporosis - Pipeline by Eli Lilly and Company, H2 2016 58 Osteoporosis - Pipeline by EndoCeutics, Inc., H2 2016 59 Osteoporosis - Pipeline by Enteris BioPharma, Inc., H2 2016 60 Osteoporosis - Pipeline by Enzo Biochem, Inc., H2 2016 61 Osteoporosis - Pipeline by Gador S.A., H2 2016 62 Osteoporosis - Pipeline by Galapagos NV, H2 2016 63 Osteoporosis - Pipeline by Glide Pharmaceutical Technologies Limited, H2 2016 64 Osteoporosis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 65 Osteoporosis - Pipeline by Haoma Medica Ltd., H2 2016 66 Osteoporosis - Pipeline by Immunovo BV, H2 2016 67 Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd., H2 2016 68 Osteoporosis - Pipeline by Ipsen S.A., H2 2016 69 Osteoporosis - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2016 70 Osteoporosis - Pipeline by Lead Discovery Center GmbH, H2 2016 71 Osteoporosis - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 72 Osteoporosis - Pipeline by Merck & Co., Inc., H2 2016 73 Osteoporosis - Pipeline by Mereo Biopharma Group Plc, H2 2016 74 Osteoporosis - Pipeline by Midway Pharmaceuticals, Inc., H2 2016 75 Osteoporosis - Pipeline by Mithra Pharmaceuticals S.A., H2 2016 76 Osteoporosis - Pipeline by NIBEC, H2 2016 77 Osteoporosis - Pipeline by Novartis AG, H2 2016 78 Osteoporosis - Pipeline by Omeros Corporation, H2 2016 79 Osteoporosis - Pipeline by Oncobiologics, Inc., H2 2016 80 Osteoporosis - Pipeline by Oscotec Inc., H2 2016 81 Osteoporosis - Pipeline by OsteoGeneX Inc., H2 2016 82 Osteoporosis - Pipeline by Osteologix Holdings Plc., H2 2016 83 Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016 84 Osteoporosis - Pipeline by Pfenex Inc., H2 2016 85 Osteoporosis - Pipeline by PhytoHealth Corporation, H2 2016 86 Osteoporosis - Pipeline by R-Pharm, H2 2016 87 Osteoporosis - Pipeline by Recursion Pharmaceuticals, LLC, H2 2016 88 Osteoporosis - Pipeline by Ribomic Inc., H2 2016 89 Osteoporosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2016 90 Osteoporosis - Pipeline by Shin Poong Pharm.Co., Ltd., H2 2016 91 Osteoporosis - Pipeline by Sinil Pharmaceutical Co., Ltd, H2 2016 92 Osteoporosis - Pipeline by STELIS Biopharma Pvt. Ltd., H2 2016 93 Osteoporosis - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 94 Osteoporosis - Pipeline by TAmiRNA GmbH, H2 2016 95 Osteoporosis - Pipeline by TechnoPhage SA, H2 2016 96 Osteoporosis - Pipeline by Terpenoid Therapeutics Inc, H2 2016 97 Osteoporosis - Pipeline by TSH Biopharm Corporation Limited, H2 2016 98 Osteoporosis - Pipeline by Uni-Bio Science Group Ltd., H2 2016 99 Osteoporosis - Pipeline by Wroclawskie Centrum Badan EIT+ Sp. z o.o., H2 2016 100 Osteoporosis - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H2 2016 101 Osteoporosis - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 102 Assessment by Monotherapy Products, H2 2016 103 Assessment by Combination Products, H2 2016 104 Number of Products by Stage and Target, H2 2016 106 Number of Products by Stage and Mechanism of Action, H2 2016 109 Number of Products by Stage and Route of Administration, H2 2016 112 Number of Products by Stage and Molecule Type, H2 2016 114 Osteoporosis - Dormant Projects, H2 2016 266 Osteoporosis - Dormant Projects (Contd..1), H2 2016 267 Osteoporosis - Dormant Projects (Contd..2), H2 2016 268 Osteoporosis - Dormant Projects (Contd..3), H2 2016 269 Osteoporosis - Dormant Projects (Contd..4), H2 2016 270 Osteoporosis - Dormant Projects (Contd..5), H2 2016 271 Osteoporosis - Dormant Projects (Contd..6), H2 2016 272 Osteoporosis - Dormant Projects (Contd..7), H2 2016 273 Osteoporosis - Dormant Projects (Contd..8), H2 2016 274 Osteoporosis - Dormant Projects (Contd..9), H2 2016 275 Osteoporosis - Dormant Projects (Contd..10), H2 2016 276 Osteoporosis - Dormant Projects (Contd..11), H2 2016 277 Osteoporosis - Discontinued Products, H2 2016 278 Osteoporosis - Discontinued Products (Contd..1), H2 2016 279
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
